VAXCYTE INC shares rose 57% in morning trading after its experimental pneumococcal vaccine matched rival products in a late-stage trial. The study evaluated the VAX-31 vaccine against established therapies in older adults. The successful trial positions the company to challenge established market leaders in the adult vaccine sector.

Trial Results Versus Industry Rivals